Atara Biotherapeutics (ATRA) Common Equity (2013 - 2026)

Atara Biotherapeutics (ATRA) has reported Common Equity for 14 consecutive years, with -$37.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity fell 5.58% year-over-year to -$37.0 million; the trailing twelve-month figure through Jun 2026 stood at -$37.0 million (down 5.58% YoY), and the FY2025 full-year result was -$38.5 million, down 107.7% from the prior year.
• Common Equity advanced to -$37.0 million in Q2 2026 per ATRA's latest filing, from -$37.3 million in the prior quarter.
• Across five years, Common Equity topped out at $500.0 million in Q1 2025 and bottomed at -$110.9 million in Q2 2024.
• Historically, Common Equity has averaged $46.4 million across 5 years, with a median of -$35.8 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Common Equity slumped 1587.36% in 2024, then jumped 608.61% in 2025.
• Over 5 years, Common Equity stood at $126.6 million in 2022, then decreased by 21.64% to $99.2 million in 2023, then slumped by 198.04% to -$97.3 million in 2024, then jumped by 60.42% to -$38.5 million in 2025, then grew by 3.91% to -$37.0 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered -$37.0 million, -$37.3 million, and -$38.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.